Clinical Research Unit of the University Hospital 12 de Octubre (i+12), Madrid, Spain.
Department of Basic Psychology, Psychobiology and Methodology of Behavioral Science, University of Salamanca, Salamanca, Spain.
Int J Geriatr Psychiatry. 2018 Jun;33(6):832-840. doi: 10.1002/gps.4707. Epub 2017 Mar 23.
We aimed to analyse the clinical utility of the Mattis Dementia Rating Scale (MDRS-2) for early detection of Alzheimer's disease (AD) and amnestic mild cognitive impairment (MCI) in a sample of Spanish older adults.
A total of 125 participants (age = 75.12 ± 6.83, years of education =7.08 ± 3.57) were classified in three diagnostic groups: 45 patients with mild AD, 37 with amnestic MCI-single and multiple domain and 43 cognitively healthy controls (HCs). Reliability, criterion validity and diagnostic accuracy of the MDRS-2 (total and subscales) were analysed. The MDRS-2 scores, adjusted by socio-demographic characteristics, were calculated through hierarchical multiple regression analysis.
The global scale had adequate reliability (α = 0.736) and good criterion validity (r = 0.760, p < .001) with the Mini-Mental State Examination. The optimal cut-off point between AD patients and HCs was 124 (sensitivity [Se] = 97% and specificity [Sp] = 95%), whereas 131 (Se = 89%, Sp = 81%) was the optimal cut-off point between MCI and HCs. An optimal cut-off point of 123 had good Se (0.97), but poor Sp (0.56) to differentiate AD and MCI groups. The Memory and Initiation/Perseveration subscales had the highest discriminative capacity between the groups.
The MDRS-2 is a reliable and valid instrument for the assessment of cognitive impairment in Spanish older adults. In particular, optimal capacity emerged for the detection of early AD and MCI. Copyright © 2017 John Wiley & Sons, Ltd.
我们旨在分析 Mattis 痴呆评定量表（MDRS-2）在西班牙老年人群中对阿尔茨海默病（AD）和遗忘型轻度认知障碍（MCI）的早期检测的临床效用。
共有 125 名参与者（年龄=75.12±6.83 岁，受教育年限=7.08±3.57 年）分为三组：45 名轻度 AD 患者、37 名遗忘型 MCI-单域和多域患者和 43 名认知健康对照组（HCs）。分析了 MDRS-2（总评分和分量表）的可靠性、标准效度和诊断准确性。通过分层多元回归分析，计算了调整了社会人口统计学特征的 MDRS-2 评分。
全球量表具有良好的可靠性（α=0.736）和与 Mini-Mental State Examination 的良好标准效度（r=0.760，p<.001）。AD 患者与 HCs 之间的最佳分界点为 124（敏感度[Se]为 97%，特异性[Sp]为 95%），而 MCI 与 HCs 之间的最佳分界点为 131（Se 为 89%，Sp 为 81%）。123 的最佳分界点对区分 AD 和 MCI 组有良好的 Se（0.97），但 Sp（0.56）较差。记忆和启动/坚持分量表在组间具有最高的区分能力。
MDRS-2 是一种可靠且有效的工具，可用于评估西班牙老年人群的认知障碍。特别是，该量表在检测早期 AD 和 MCI 方面具有最佳能力。版权所有©2017 年约翰威立父子公司。
